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MAGNESIUM AND CARDIOVASCULAR DISEASE 
 
Magnesium has been associated with many health conditions. Many studies have shown 
inconsistent results on the relationship between magnesium (both serum and dietary) and risk 
of CVD related outcomes. 
    The aim of this thesis was to investigate the association of serum magnesium concentration 
with risk of CVD related incidence and mortality. 
    The subjects for this study were 2540 eastern Finnish men who participated in the baseline 
study of Kuopio Ischemic Heart Disease Risk Factor Study (KIHD) and whose information 
regarding serum magnesium concentration was obtained. KIHD is an ongoing population 
based prospective follow up study. The baseline study involved two cohorts who were 
followed up. The first cohort enrolled men aged 54 years from 1984 to 1986 (n =1166) and the 
second cohort enrolled men aged 42, 48, 54 and 60 years from 1986 to 1989 (n =1516).  
Serum magnesium concentration and other factors were assessed at the baseline. All the 
cardiovascular events were ascertained from the medical records of hospitals and death 
certificates. Cox regression analysis was used to calculate the hazard ratio of all the outcome 
variables. 
    Before adjusting for confounders, the risk of fatal CVD, CHD and SCD decreased with a 
unit increase in serum magnesium concentration. But after multivariable adjustment for 
potential confounders only the risk of fatal CVD and CHD decreased by 9% (HR: 0.91; 95% 
CI: 0.85, 0.96), and 9% (HR: 0.91; 95% CI: 0.85, 0.98) respectively with a unit increase in 
serum magnesium concentration. Similarly, when serum magnesium concentration was 
modeled into fourths by quartiles, the findings showed decrease in risk of CVD, CHD 
mortality in all quartiles when compared to the lowest serum magnesium concentration. 
However there was not much difference in the HR among the fourths. The multivariable 
adjusted HR, comparing the highest quartile with the lowest quartile of serum magnesium 
concentration were 0.0.74 (95% CI: 0.57, 0.95) for CVD death, 0.72 (95% CI: 0.53, 0.97) for 
CHD death. However the incidence of CVD, CHD, AMI and stroke (also ischemic and 
hemorrhagic) were not found to be associated with baseline serum magnesium concentration. 
    In conclusion serum magnesium concentration was found to be inversely associated with 
fatal CVD, CHD in this large cohort prospective study of men. SCD was significantly 
inversely associated with total serum magnesium concentration only when it was not adjusted 
for confounders. Thus low serum magnesium is a stronger risk factor for fatal than non fatal 
CVD outcomes.  
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1 INTRODUCTION 
 
Cardiovascular diseases (CVD) are one of the leading causes of death worldwide, explaining 
17.3 million deaths (30% of all deaths) worldwide in the year 2008. Of these total deaths, 7.3 
million were because of coronary heart disease and 6.2 million were due to stroke (WHO 
2011). According to Statistics Finland, diseases due to the circulatory system were the leading 
cause of death in both men and women in Finland in the year 2012 (causes of death 2012, 
Statistics Finland). Ischemic heart disease is the main cause of death in Finns among the 
circulatory diseases. However there has been decrease in the trend from 47 to 39 percent in the 
past twenty years (causes of death 2012, Statistics Finland). Behavioral life style factors which 
include unhealthy diet, physical inactivity, and harmful use of alcohol and tobacco are 
associated with the occurrence of cardiovascular diseases (WHO 2011). 
 
Several epidemiological studies suggest that diet plays important role in determining CVD. 
Increase in intake of salt, saturated fat and trans fat have shown increased risk of CVD 
whereas increase in intake of fruits and vegetables, polyunsaturated fat, monounsaturated fat, 
fiber have shown protective effect (O Flaherty et al. 2012; Scarborough et al. 2011). There 
was a decline in the incidence and mortality of CHD in Finland during the period 1982 to 
1987, which was due to the changes in the major risk factors (Laatikainen et al. 2005). 
Another study done in United Kingdom has shown that changing the dietary pattern that is 
slight decrease in the consumption of harmful macronutrients and increasing the consumption 
of fruits and vegetables could reduce the total CVD death by approximately 20% (O Flaherty 
et al. 2012). Mediterranean dietary pattern has shown protective effect on cardiovascular 
disease and many cancers (Panico et al. 2014). 
 
In recent period the intake of micronutrient is decreasing. The consumption of micronutrients 
like potassium, calcium and magnesium is found below the recommended value in many of 
the studies. Thus increase in intake of vegetables, fruits, and dairy should be recommended 
(Gallaghar et al. 2014; Mirzaeian et al. 2013). Along with all other nutrients present in diet, 
the importance of magnesium intake has also been studied and understood. Many studies have 
shown association between dietary magnesium intake and serum magnesium and the incidence 
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of CVD whereas some studies have failed to prove this. Thus the effect of magnesium on 
CVD morbidity and mortality is unclear (Eliat-Adar et al. 2013). 
 
This study shows us the role of magnesium in the occurrence of outcome variables CVD, 
CVD death, AMI, CHD, CHD death, stroke, ischemic stroke, and hemorrhagic stroke, SCD or 
SCA. Thus from this study we will know if increasing or decreasing magnesium has protective 
effect on various cardiovascular events and death. 
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2 LITERATURE REVIEW  
 
2.1 Magnesium 
 
Magnesium is the fourth most common cation found in the body and the second most common 
intracellular cation. It is important to perform many physiological roles for different body 
functions like enzyme function, direct enzyme activation including many ATP generating 
reactions, membrane function, structural function which includes synthesis of RNA, DNA and 
protein, and acts as calcium antagonist in muscle contraction (Jahnen-Dechent and Ketteler. 
2012). It also has important role in cell cycle, mitochondrial integrity, modulating ion 
transport (Romani 2011; Swaminathan 2003). The  binding of magnesium with important 
intracellular anionic –liganda especially ATP and the competition with calcium for binding 
sites on protein membranes are the most important role of magnesium that help to perform 
those function (Swaminathan,2003). It also acts as a cofactor for more than 300 enzymatic 
reactions that includes energy metabolism and nucleic acid synthesis and cell replication. It is 
also important for normal neurological and muscular function, and cardiac excitability. A 
study done in human volunteers showed that consuming magnesium deficient diet resulted in 
negative magnesium balance but did not affect the serum magnesium concentration. This also 
affected the calcium, potassium and cholesterol metabolism (Nielsen 2004). 
 
2.2 Body content and distribution of magnesium 
 
Adult human body contains approximately 1mol (21-28g) Mg. Of total magnesium content in 
human body, less than 1% is found in serum and red blood cells. About 53% that is one half of 
the magnesium is found between bones, 27% in intracellular compartment of muscles, and 
19% in soft tissues, 0.5%in erythrocyte and 0.3% in serum (Fawcett 1999). Bone magnesium 
can be used in the state of magnesium deficiency. It stays in equilibrium with ionized 
magnesium of extra cellular fluid and antagonizes calcium during muscle contraction (de Baaij 
et al. 2012). The availability of magnesium in bone decreases with age and therefore might not 
be completely available when there is magnesium deficiency (Maguire and Cowan 2002). 
Serum magnesium is present in three different states; free, complexes to anions and bound to 
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protein. Approximately 62% of the plasma magnesium is found circulating in ionized state, 
approximately 33% are protein bound mostly to albumin and approximately 5% are complexes 
to anions, citrates and phosphate (Fawcett et al. 1999; Elin 1987). However ionized 
magnesium is the one which is most involved in biological activity. The reference value for 
magnesium concentration in blood plasma ranges from 0.65 to 1.05 mmol/l for adults (Saris et 
al. 2000) and for ionized magnesium reference value ranges from 0.53 to 0.67 mmol in normal 
healthy people (Altura et al. 1991). 
 
2.3 Magnesium intake 
 
Magnesium concentration depends on the magnesium intake from food and drinking water. 
Whole seeds, unmilled grains, green leafy vegetables (rich in magnesium containing 
chlorophyll) legumes and nuts are the most important sources of dietary magnesium. Meat, 
fish, fruits are also good sources of magnesium. Drinking water especially hard water is also 
one of the sources of magnesium which might account for almost 10% of daily magnesium 
intake. The absorption of magnesium is influenced by various dietary factors either promoting 
or inhibiting the absorption. Absorption of magnesium can be inhibited by phytate, fibre, 
alcohol or excess of calcium and phosphate. Processing and refining of food leads to loss of 
magnesium content in food (Saris et al. 2000; Shils et al. 2006). The effect of vitamin D in 
magnesium absorption is still unclear. Some studies have shown that vitamin D and its active 
metabolites increases intestinal magnesium absorption in normal human beings and also in 
patients with chronic renal failure (Shils et al. 2006). The normal serum magnesium 
concentration or (Mg2+) ranges between 0.75 and 0.95mmol/l (Weisinger and Bellorin-Font 
1998).  
 
The recommended dietary allowance of magnesium for male is 350 mg per day and for female 
it is 280 mg per day. But the requirement for female during pregnancy is increased to 355 mg 
per day. Several studies have shown that nowadays magnesium intake in Western countries is 
below the recommended value (Saris et al. 2000). 
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2.4 Magnesium homeostasis 
 
Magnesium homeostasis is maintained by intestine, the bone and the kidney. In brief 
magnesium is absorbed through gut, stored in bones and excreted through kidney if excess. 
Intestinal absorption of magnesium was inversely related to magnesium intake in a healthy 
volunteer which ranged from 65% at low intake and 11% at high intake (Fine et al. 1991). 
Homeostasis of magnesium depends on its intake, efficiency of intestinal and renal absorption 
and also excretion and many other relevant factors like hormones. Two pathways that is 
paracellular and trans cellular pathways are involved in the absorption of Mg2+. Paracellular 
pathway which is a passive mechanism absorbs Mg2+ through small spaces between epithelial. 
The trans cellular pathway involves movement of Mg2+ to the blood through the interior of 
epithelial cell. Around 30 to 40% of normal dietary intake of magnesium is absorbed through 
intestine. Jejunum and ileum are the important sites where magnesium absorption takes place. 
After 1 hour of ingestion the absorption begins and continues for 2 to 8 hours. After 12 hours 
the ingested material reaches large bowel in human where little or no absorption takes place 
(Shils et al. 2006; de Baaij et al. 2012). 
 
 Kidney plays an important role in regulating magnesium homeostasis especially in filtration 
and reabsorption process. Of the total magnesium present in the body 10 % (approx 100mmol 
or 2400mg) is filtered through glomeruli daily in normal healthy human. Of filtered 
magnesium only 5% is excreted through urine. 90 to 95% of filtered magnesium is reabsorbed 
in different segments of nephron. Approximately 10-25% of magnesium is reabsorbed via 
paracellular transport in proximal tubule. The major site where 65 to 75% of the magnesium is 
reabsorbed is the thick ascending loop of henle by the same paracellular mechanism. Only less 
amount of magnesium 5 to 10% is reabsorbed in distal convoluted tubule by active 
transcellular pathway (Dai et al. 2001; de Baaij et al. 2012). 
 
2.5 Hypomagnesia 
 
The level of magnesium in our body might not always be the same. Hypomagnesia indicates 
depletion of body magnesium. It is defined as hypomagnesia when the serum magnesium is 
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less than 1.8mg/dl (<0.74mmol/l). Most of the cases of hypomagnesia are asymptomatic. 
Symptomatic cases are seen only when serum magnesium falls below 1.2mg/dl (Assadi 2010). 
Magnesium deficiency or hypo magnesia can occur due to various reasons and mechanisms. 
Some of the reasons for magnesium deficiency are redistribution of magnesium, reduction in 
dietary intake and intestinal absorption, renal loss, endocrine causes, diabetes mellitus, 
alcohol, drugs (Fawcett et al. 1999; Swaminathan 2003). 
 
2.5.1 Causes of hypomagnesia 
 
Hypomagnesia due to redistribution: Hypomagnesia is seen when the magnesium from 
extracellular fluid moves to cells and bones in refeeding syndrome, during correction of 
acidosis, and in hungry bone syndrome which is seen in patient with diffuse osteoblastic 
metastases (Swaninathan 2003). 
 
Gastrointestinal causes: The absorption of magnesium might reduce in cases of chronic 
diarrhea, malabsorption syndrome and after extensive bowel resection (Swaninathan 2003). 
 
Renal loss: Urinary Mg2+ loss might be because of the defect in renal tubular magnesium 
reabsorption. It might be also because of reduction in sodium reabsorption as proximal tubular 
magnesium reabsorption is proportional to sodium and calcium reabsorption (Swaminathan 
2003; Weisenger et al. 1998). Excess renal excretion can be another cause of magnesium 
depletion. Use of diuretics can result in magnesium wasting, loop of henle being the major site 
for magnesium reabsorption (Shils et al. 2006). 
 
Many congenital disorders affecting renal tubular reabsorption of magnesium has been                                                 
described. Some of them are barters syndrome, Gitelmans syndrome, Familial hypomagnesia, 
Antenatal Bartters syndrome (Assadi 2010; Swaninathan 2003; De Franciso and Rodriguez 
2013). 
 
Diabetes: Among all the disorders due to magnesium deficiency diabetes mellitus is the most 
common. Renal magnesium wasting and osmotic diuresis generated by hyperglycosuria are 
14 
 
the causes of magnesium depletion in diabetes patient. Depletion in magnesium also affects 
the insulin secretion and insulin resistance. This may be due to abnormal glucose metabolism 
as Mg is involved in this cycle. It may also affect the activity of tyrosine kinase at the insulin 
receptor (Takaya et al. 2004). Fasting blood glucose, glycated hemoglobin, albumin excretion 
and the duration of diabetes are correlated with magnesium deficiency (Corsonello et al. 
2000). Hypomagnesia is also associated with type 2 diabetes mortality (Curiel-Garcia et al. 
2008; Lecube et al. 2012; S P et al.2013; Dasgupta et al. 2012). 
 
Alcohol: Hypomagnesia is found in chronic alcoholism with an incidence rate of 29.8%. The 
reason for hypomagnesia among alcoholic may be due to poor nutritional intake, diarrhea, 
vomiting, malabsorption as a result of chronic pancreatitis or liver disease, vitamin D 
deficiency, decrease renal tubular dysfunction, and the property of ethanol that alters ionic 
permeability (Stasiukyniene 2002; Romani 2008). 
 
Hypo magnesia may further lead to various diseases like diabetes, cardiovascular disease, and 
osteoporosis. The most common manifestation of hypo magnesia is cardiac arrhythmias, 
hypocalcaemia and blood pressure (Swaminathan 2003). 
 
2.6 Hyper magnesia  
 
Hypermagnesia, the excess of magnesium in body may be the result of high intake of 
magnesium salt or magnesium containing drugs which is mostly seen in people with renal 
failure or reduced renal function. Occurrence of hyper magnesia is very rare but it may results 
in various neuromuscular, cardiovascular manifestation and hypocalcaemia. Higher level of 
magnesium also leads to cardio toxicity (Swaminathan 2003). 
 
Chronic kidney disease or end stage kidney disease is the only strong clinical predictor for 
hyper magnesia and net positive magnesium balance. Dialysis patients have higher magnesium 
level (Spiegel 2011). 
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2.7 Measurement of magnesium 
 
Total body magnesium cannot be measured by a single test. Different measurement techniques 
are available to measure the magnesium level in various parts of human body (Jahnen-Dechent 
and Ketteler 2012): 
a) Concentrations in serum, red blood cell, blood mononuclear cells or muscles help to 
estimate the tissue magnesium level. 
b) Isotopic analysis and evaluation from renal mg excretion and retention helps in metabolic 
assessment of Mg2+ balance. 
c) Fluorescent probes, nuclear magnetic resonance spectroscopy, or ion selective electrodes 
can be used to determine Mg2+ level.  
 
Assessing total serum magnesium concentration is the easiest, practicable, and inexpensive 
method of measuring magnesium and its changes in status. However it does not correlate 
accurately with total body magnesium content (Jahnen-Dechent and Ketteler 2012). Serum 
magnesium is more preferred than plasma magnesium because additive such as anticoagulant 
may bind with plasma Mg2+ affecting the examination (Noronha and Matuschak 2002). Serum 
magnesium concentration can also be taken as a good way of determining magnesium status 
because they correlate with ionized (Huijgen et al. 1998; Koch et al. 2002) and intracellular 
magnesium (Huijgen et al. 1998). 
 
2.8 Clinical manifestation 
 
2.8.1 Magnesium and cardiovascular manifestation 
 
Magnesium depletion causes various cardiac manifestation, among which cardiac arrhythmia 
is an important complication where both extracellular and /or intracellular magnesium has 
been implicated. Prolonged QTc interval is found to be associated magnesium deficiency 
(Seelig 1969) and also magnesium supplementation has shown to reduce QTc interval in 
patient with normal serum magnesium (Krasner et al. 2002). The competition between Mg2+ 
and Ca2+ to bind in the same site of myocardial contractile protein may be the reason for the 
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affect of Mg2+ and calcium (Ca2+) on myocardial contractility (Chakraborti et al. 2002). A 
decrease in myocardial Mg2+ decreases intracellular potassium (K+), which results in less 
negative resting membrane potential. This leads to prolonged QTc interval and increase the 
risk of ventricular arrhythmia (Chakraborti et al. 2002). 
 
Neuroprotective and vasodilatory effect of magnesium can improve the clinical outcome of 
patient suffering from subarachnoid hemorrhage and also can reduce the chance of cerebral 
ischemia after subarachnoid hemorrhage (Van den Bergh et al. 2004). 
 
Increase in magnesium intake was found to be inversely associated with coronary artery 
calcification and abdominal aortic calcification. The association was stronger in female than in 
male. Thus magnesium might have role in preventing stroke and fatal coronary heart disease 
(Hruby et al. 2014). 
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2.9 Magnesium and cardiovascular disease 
 
According to Japan collaborative cohort (JACC) study, dietary intake of magnesium was 
inversely associated with mortality from hemorrhagic stroke in men and with total and 
ischemic stroke, coronary heart disease, heart failure in women aged 40-79 years (Zhang et al. 
2012). 
 
A recent prospective study conducted in Spain among the Mediterranean population who were 
at risk of developing CVD, showed that the increase in magnesium intake lowers the risk of 
cardiovascular events and death, also after adjusting for various confounders (Guasch-Ferre et 
al. 2014). Similarly a prospective cohort study in men showed no relation between magnesium 
intake and all cause CVD and cancer mortality (Kaluza et al. 2010). Serum magnesium was 
not found to be associated with subsequent development of hypertension, CVD or all-cause 
mortality in the Framingham heart study offspring cohort (Khan et al. 2010). In another 
prospective study of men highest serum magnesium concentration was found to reduce the 
risk of cardiovascular mortality by 40% (Leone et al. 2006). 
 
There are many risk factors that affect the association of serum and dietary magnesium with 
cardiovascular events. A study done in India among people with coronary artery disease 
showed that various cardiovascular risk factors are significantly correlated with serum 
magnesium and dietary magnesium intake. Risk factors like hypertension, diabetes, smoking, 
dyslipidemia was found to be inversely correlated with magnesium level. And also most of the 
people having these risk factors were having low dietary and serum magnesium level 
compared to patient without the risk factors (Mahalle et al. 2012). Atherosclerosis Risk in 
communities study done among black and white population showed that mean magnesium 
level is significantly lower in people having diabetes, hypertension and CVD compared to 
disease free population even after adjusting for age and BMI. In contrast mean dietary 
magnesium intake was generally found to be low in disease free population. Further there was 
seen an inverse correlation between magnesium level (serum and dietary) and few selected 
variables such as systolic blood pressure, HDL cholesterol, fasting insulin, smoking (Ma et al. 
1995). In a study done among haemodialysis patient, the risk factors for CVD like age, body 
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mass index, systolic blood pressure before dialysis, serum lipid and calcium profile were not 
found to be correlated with serum magnesium level (Khatami et al. 2013). Thus magnesium 
can be one of the related causes to CVD. 
 
In a prospective cohort study done among male high serum magnesium value was found to 
decrease the risk of cardiovascular mortality by 40%. It remained the same even after 
adjusting the nutrient intake (Leone et al. 2006). Another study conducted in male population 
also revealed that lower magnesium concentration is associated with increased risk of all-
cause mortality and cardiovascular mortality even after adjustment for cardiovascular risk 
factors and drug therapy and left ventricular mass in the baseline (Reffelman et al. 2011). In a 
study done among hemodialysis patient low serum magnesium was found to be independent 
predictor for CVD mortality (Sakaguchi et al. 2014). In another study done among population 
of ambulatory heart failure, it was seen that the cardiovascular mortality is a bit more in 
patient with low serum magnesium (Adampoulos et al. 2009). 
 
2.10  Magnesium and coronary heart disease 
 
Increase in magnesium intake among men was associated with modest lower risk CHD 
compared to the lowest quartile after adjusting for its confounders (Al-Delaimy et al. 2004). 
Similarly, a case control study conducted in Serbia, explained that intake of foods high in 
magnesium level (cereals, legumes and vegetables) was significantly less in subjects with 
coronary heart disease compared to control groups, showing an inverse association of 
magnesium intake with risk of CHD (Stevanovic et al. 2011). In a nurses’ health study 
conducted to examine the association of plasma and dietary magnesium with the risk of 
coronary heart disease, higher magnesium intake was not found to be associated with decrease 
risk of total CHD after adjusting for various known risk factors like alcohol intake, diabetes, 
hypertension, omega 3 fats, calcium and many others. But the risk of fatal CHD was decreased 
by 36% in the highest quartile when compared to the lowest quartile of magnesium intake. 
Regarding the plasma magnesium, no linear inverse association was seen after adjusting for 
various potential confounders (Chiuve et al. 2013). Plasma magnesium was not found to be 
associated with IHD but urinary magnesium excretion was found to be associated with IHD in 
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a nonlinear trend (Joosten et al. 2013). There was slight difference in the mean concentration 
of ionized magnesium in patient with stable coronary disease and healthy population but it was 
not found to be statistically significant. The difference was a bit more in patient having both 
arterial hypertension and coronary artery disease compared to healthy population which was 
also not statistically significant (Kozielec et al. 2005). 
 
A study conducted among US adults showed that the serum magnesium is more strongly 
associated with mortality of all cause and ischemic heart disease compared to ischemic 
incidence. Thus increase in serum magnesium defines significant lower in risk of ischemic and 
all-cause mortality (Ford 1999). In ARIC study lowest risk for CHD incidence among both 
men and women was found in the highest quartile of serum magnesium concentration 
compared to the lowest quartile after adjusting for its confounders (Liao et al. 1998). 
 
2.11  Magnesium and stroke 
 
In a study done among health professionals it was found that magnesium was inversely 
associated with the risk of stroke when adjusted for age but was not the same when further 
adjusted for potassium and calcium which had positive correlation with the magnesium 
(Ascherio et al. 1998). There was not any association between dietary intake of magnesium 
and total stroke, intracerebral hemorrhage, or subarachnoid hemorrhage after adjustment for 
other risk factors in a study done among Swedish female (Larsson et la. 2011). Similarly 
another study done among Finnish male smokers showed that the high magnesium intake was 
significantly associated with the reduction in risk of cerebral infarction also after adjusting for 
other potential confounders. But there was not found any association between subarachnoid 
and intracerebral hemorrhage though the risk of getting subarachnoid hemorrhage was found 
very high in third (1.64, 95% CI: 1.01, 2.64) and fourth quartile (1.83, 95% CI: 1.15, 2.93) 
(Larsson et al. 2008). In a trail done among adults having aneurysmal subarachnoid 
hemorrhage mean serum magnesium concentration was higher in group receiving magnesium 
sulfate (MgSO4) than in placebo (receiving saline) group. There was seen worse clinical 
outcome in the highest plasma concentration of magnesium sulfate (MgSO4) group and in the 
third and fourth quartile in the placebo group. However there was association between good 
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clinical outcome and third and fourth quartile of serum magnesium in the placebo group. Thus 
this study did not provide satisfactory result to say increasing serum magnesium reduces the 
risk of subarachnoid hemorrhage (Wong et al. 2010). In another clinical trial, patient 
presenting within 12 hours of clinically diagnosed acute middle cerebral artery stroke were 
randomized to magnesium sulfate (MgSO4) and placebo group. Magnesium level started to 
rise over 24 hour after the infusion and remained significantly high at 48 hours. There was 
seen fewer cases of death and disability in magnesium treated patient (30%) than placebo 
group (40%) at 3 months (Muir et al. 1995). 
 
A case control study done in China showed that the mean dietary intake of magnesium was 
lower in cases (patient with ischemic stroke) than in controls (patient without ischemic stroke). 
There was a decrease in risk of stroke with an increase in dietary magnesium level, with the 
lowest risk in the highest quartile of magnesium intake. There was a similar relation also with 
dietary calcium level (Liang et al. 2011). In a cohort study done to know the relationship 
between tap water hardness and risk of stroke mortality and IHD mortality, there was not 
found any association between them among both men and women. When the analysis was 
restricted to the subject with 20% lowest dietary intake, there was seen a protective effect of 
tap water hardness in the fourth quartile compared to the lowest for stroke among men but 
there was not seen any association with IHD mortality (Leurs et al. 2010). Also dietary intake 
of magnesium from water has shown protective effect on the risk of cerebrovascular disease 
(Yang 1998). Arthrosclerosis risk in communities study cohort showed that the inverse 
association of ischemic stroke with dietary magnesium intake is weaker than that with serum 
magnesium level. But when other risk factors like systolic blood pressure, diabetes mellitus 
and use of anti hypertensive medication was added the association with serum magnesium 
reached to a no significant level. Having both dietary and serum magnesium greater than the 
median value was associated with 36% lower risk of ischemic stroke (Ohira et al. 2009). 
Although magnesium intake had modest effect on risk of ischemic stroke, the inverse 
association was no longer significant when adjusted for other cardiovascular risk factors, 
including hypertension in middle aged American women (Iso et al. 1999). The other dietary 
minerals like potassium and calcium can also affect the association between magnesium intake 
and incident of ischemic stroke and CHD (Iso et al. 1999; Al-Delaimy et al. 2004).  
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2.12  Magnesium and AMI 
 
A cohort study in women showed no significant association between magnesium intake and 
the incidence of total cardiovascular disease, coronary heart disease, non-fatal MI or stroke. 
However lower risk of total and ischemic stroke was associated with high intake of 
magnesium (Song et al. 2005). Low serum magnesium was associated with the increase risk of 
atrial fibrillation. The risk of atrial fibrillation increased by 54% in the lowest quartile 
compared to the highest quartile of serum magnesium (Khan et al. 2013). 
 
Also environmental risk factors can explain the variation in the occurrence of CHD among 
different places. An ecologic population based study done in Finland among men aged 35-74 
years suggested that there was a relationship between hardness of water and occurrence of 
acute myocardial infarction. It had shown that the increment in magnesium level in ground 
water decreased the risk of AMI. It also suggested that the increase in Ca:Mg ratio increased 
the risk of AMI as both of these elements were found to be highly correlated. Similarly when 
the age was standardized the risk of AMI was highest in the lowest quartile of magnesium and 
was lowest in the highest quartile of magnesium (Kousa et al. 2006). Whereas another similar 
study done in Taiwan based on ground water magnesium level did not show protective effect 
on the risk of death from AMI with OR of 1 (95% CI: 0.93, 1.08) and 1.09 (95% CI: 0.99, 
1.19) respectively, for the two higher magnesium level after adjusting for calcium (Yang et al. 
2006). Serum magnesium concentration was found to be lower in south Indian male 
population having AMI than in the controls. And also there was significant correlation 
between serum magnesium level and other cardiac biomarkers (Ramasamy et al. 2013). 
 
A clinical trial, done among patients with suspected acute myocardial infarction did not show 
significant difference in the incidence of rhythm disturbance for ventricular fibrillation, 
ventricular tachycardia, supraventricular tachycardia or heart block of any degree among 
placebo and MgSO4 receiving group. Sinus bradycardia was more observed in MgSO4 group. 
Thus MgSO4 did not show significant effect on arrhythmia in AMI (Roffe et al. 1994). In 
another clinical trial study serum magnesium was found to be lower in patients with AMI. 
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There was seen significant lower incidence of arrhythmia in patients receiving magnesium 
compared to placebo group (Gyamlani et al. 2000). 
 
A study done in male Wistar rats showed that when MgSO4 was infused intravenously before 
reperfusion there was significant reduction in formation of thrombus in vivo (Ravn et al. 
1997). 
 
2.13   Magnesium and sudden cardiac death 
 
In a prospective cohort study conducted among women, the relative risk of sudden cardiac 
death was lower in highest quartile of dietary and plasma magnesium. But the association was 
seen stronger in highest plasma magnesium level (RR: 0.23, 95% CI: 0.09, 0.60) with a 
significant linear trend (Chiuve et al. 2011). ARIC study conducted in middle aged biracial 
population showed that the risk of sudden cardiac death was decreasing in a linear trend from 
the lowest serum magnesium level to the highest serum magnesium level. But when it was 
adjusted for diabetes, hypertension and use of diuretics the association was weakened showing 
slightly less protective effect (Peacock et al. 2010). 
 
In a meta-analysis of prospective cohort study magnesium intake was found to be inversely 
associated with ischemic stroke but not with intracerebral hemorrhage or subarachnoid 
hemorrhage (Larson et al. 2012). 
 
According to the study done in animal, inadequate intake of magnesium resulted in 
development of increase atherosclerotic plaque in rabbits (King et al. 2009). In a study 
conducted in rats, higher serum cholesterol and total phospholipid was found among 
magnesium deficient rats than in controls (Cunnane et al. 1985). 
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3 AIM OF THE STUDY 
 
 The aim of this thesis is to explore the association of magnesium with cardiovascular events 
among men from Eastern Finland. 
 
The specific aims of the study are to: 
 To assess the association between magnesium and risk of nonfatal events, namely 
CVD, AMI, CHD, stroke, ischemic stroke, hemorrhagic stroke in a population based 
KIHD study conducted in 1984 to 2011. 
 To assess the association between magnesium and risk of fatal events, namely CVD 
death, CHD death and SCD or SCA in a population based KIHD study conducted in 
1984 to 2011. 
 
4  METHODS 
 
4.1 Study population 
 
This study used the data from Kuopio Ischemic Heart Disease Risk Factor Study. The KIHD 
study is an ongoing population based cohort study being conducted in Eastern Finland to 
investigate the risk factors for cardiovascular disease and other chronic disease in middle aged 
men and women. 
 
A baseline study was conducted between March 1984 to December 1989 which included 3235 
men (of which 82.9% participated) living in Kuopio and neighboring rural communities. The 
baseline study was conducted in two cohorts. The first cohort carried out between 1984 to 
1986 enrolled 1,166 men, aged 54 years and the second cohort carried out between 1986 to 
1989 enrolled 1516 men aged 42, 48, 54 or 60 years. 
 
This baseline study was followed by 11 year follow up study which included 854 men from 
second cohort and 920 randomly selected post-menopausal women aged 53-73 years from the 
same area. The study further proceeded to 20 year follow up. In order to assess the dietary 
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intake of nutrients, four day food records were maintained during the baseline and 11 year 
follow up examination. This current study includes 2540 men from the baseline whose serum 
magnesium level has been determined.  
 
4.2 Ethical consideration 
 
KIHD study has been approved by the ethical committee of University of Eastern Finland and 
also the study subjects gave an informed consent. 
 
4.3 Data collection 
 
There was three set of self-administered questionnaire that were emailed to the participants 
before they came for health checkups. The first questionnaire included the information 
regarding demographic characteristics, major life events, leisure time activities, family life, 
socioeconomic background, childhood circumstances and health behavior such as smoking, 
physical activity, alcohol consumption, health status, drug use. The other two questionnaires 
were related to psychosocial wellbeing. The participants were called for a health examination 
where they were also interviewed by a research nurse for some of the questions in the 
questionnaire. Blood sample was taken at the same time. 
 
4.4 Measurements 
 
4.4.1 Blood sample 
 
The blood samples were collected from subjects between 8 and 10 am on Tuesday, 
Wednesday or Thursday at the baseline examination. The subjects were abstained from taking 
alcohol for 3 days, smoking and eating for 12 hours prior to the sample collection. Further 
description regarding the measurement of serum lipids (Salonen et al. 1991) and lipoproteins, 
blood glucose, blood hemoglobin, ferritin, copper, has already been explained in the previous 
studies (Salonen et al. 1992; Kurl et al. 2006). Diabetes was either defined as self-reported or 
fasting blood glucose ≥8.0 mmol/l. 
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4.4.2 Dietary intake 
 
Dietary intake of food was assessed with the help of well instructed and interview checked 4 
day food record during the baseline examination by household measure. Data on calcium, 
fiber, alcohol intake and energy was obtained from 4 day food record.  A software named 
Nutrica version 2.5 was used to calculate the nutrients intake. The software mainly uses the 
Finnish values for the nutrients in the composition of food, taking into account the loss of 
vitamins during food preparation. It’s software with a database on 1300 food items and dishes 
and 30 nutrients. A research institution named Research Center of the Social Insurance 
Institution of Finland has developed this software (Voutilainen et al. 2001). 
 
All the dietary nutrients were adjusted for energy intake using the residual methods. The 
energy adjustment was done in order to balance the differences in the energy requirements 
among individuals (Voutilainen et al. 2001). 
 
4.4.3 Assessment of serum magnesium 
 
The venous blood samples were collected into trace-element and centrifuged at 1000g for 10 
minutes. All the precautions were taken to prevent the sample from contamination during 
collection and laboratory work. The polyethylene tubes used in the analysis were washed with 
5% nitric acid and rinsed with deionized water. Samples were stored at -20 centigrade until the 
assay. The method used to measure serum magnesium in this study was atomic absorption 
spectrometry (Perkin Elmer Zeeman 5000, Perkin Elmer, Norwalk, CT, USA) where acetylene 
–air (1:4) flame technique was used. Serum magnesium was diluted in a ratio of 1:50 with 
distilled water. The wavelengths were 185.2nm for magnesium. The between-run CV% for the 
method is 2.4 (37 assays). (Saaranen et al. 1987) 
 
4.4.4 Assessment of other covariates 
 
The data on age, education, and current number of cigarettes, cigars or a pipe smoked daily, 
time period of regular smoking (years), history of CVD, presence of hypertension, and use of 
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antihypertensive drugs, use of diuretics and aspirin medication was obtained using self-
administered questionnaire. Re interviews were conducted again by a physician to collect the 
information on medical history. Family history of CVD was considered as positive if 
biological mother, father, brother and sister of participant had CVD history.  
 
A subject was defined as smoker if he had ever smoked cigarettes, cigars or a pipe on a regular 
basis or within the past 30 days (Salonen et al. 1992). 
 
Resting blood pressure was measured by a nurse on the first examination day with a random 
zero sphygmomanometer. And the mean of all 6 measurements (3 supine, 1 standing, 2 sitting) 
was used as the final mean systolic and diastolic blood pressure (Salonen et al. 1992). 
 
Physical activity was assessed from 12 months history using leisure time physical activity 
questionnaire which had the information on frequency, average duration and intensity, for 
each activity performed. Mean intensity of physical activity was expressed in MET (Lakka et 
al. 1994). 
 
Energy expenditure (kcal/week) was measured for each physical activity by multiplying the 
metabolic index of activity (in metabolic equivalent *hour/week) by body weight in kilograms 
(Lakka et al. 1994). 
 
Body mass index was calculated as the ratio of weight in kilograms divided by the square of 
heights in meters (kg/m2). 
 
Serum fatty acids were measured with capillary gas chromatography (Virtanen et al. 2005). 
 
4.5 Follow up ascertainment 
 
Information on stroke, AMI and CHD events between the periods 1984 to 1992 were collected 
through FINMONICA register. It’s the Finnish version of WHO MONICA project 
(Multinational Monitoring of Trends and Determinants in Cardiovascular Diseases). 
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Information on other cardiovascular outcome events throughout and information on AMI, 
stroke and CHD later from 1992 to 2011 were obtained from the National Hospital Discharge 
Register data by computer linkage and death certificates registers using Finnish personal 
identification code. In a manner similar to FINMONICA criteria, information on diagnosis 
was collected from hospital and was classified by a neurologist and cardiologist. However the 
FINMONICA register data were rechecked annually with the data obtained from hospital 
register and death register. There were no losses to follow up. The events were coded 
according to tenth ICD codes (Kurl et al. 2006). The tenth ICD codes for all outcomes are as 
follow: Stroke (I60 –I64), ischemic stroke (I63) and hemorrhagic stroke (I60-I61) CVD (I00-
I99), CHD (I20-I25), AMI (I20-I22), cardiac arrest (I460, I490). The codes for deaths were the 
same. 
 
All the events of stroke, ischemic and hemorrhagic stroke that occurred from the study entry to 
2004 were included. Whereas all the events of CVD, CVD death, CHD, CHD death, AMI, 
SCD or SCA that occurred from the study entry until 2011 were included in this study. 
 
4.6 Statistical analysis: 
 
The descriptive data were presented in the form of mean and standard deviation for continuous 
variables and in numbers and percentages for categorical variables. The background 
characteristics were presented according to the quartiles of serum magnesium level. Serum 
magnesium concentration was categorized into fourths Q1, Q2, Q3 and Q4 by three quartiles 
in an ascending order moving from the lowest (Q1) serum magnesium concentration to the 
highest (Q4) serum magnesium concentration. 
 
Our aim in this study was to find the association between exposure (magnesium) and outcome 
(cardiovascular events) keeping in consideration all the confounding factors (risk factors).  
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List of dependent variables, outcome variables and possible confounders used in this study 
DependentVariable(Exposure) Outcome variables Possible confounders 
Serum magnesium concentration 
(mg/l) 
Dietary magnesium intake (mg/d) 
 
CVD 
CVD death 
AMI 
CHD 
CHD death 
SCD or SCA 
Stroke 
Ischemic stroke 
Hemorrhagic stroke 
 
Age (years) 
Years of education  
BMI (kg/m2) 
Energy (KJ/d) 
Energy expenditure (Kcal/d) 
Alcohol/week (g/d) 
Mean SBP (mmHg) 
Mean DBP (mmHg) 
LDL–chol (mmol/l) 
HDL– chol (mmol/l) 
Calcium (mg/d) 
Total serum n-3 (% of 
energy intake) 
Fiber (g/day) 
DU-k (mmol/d) 
Smoking (yes, no) 
Diabetes (yes, no) 
CVD in family (yes, no) 
Magnesium supplementation 
(yes, no) 
Elevated BP (yes, no) 
Aspirin medication (yes, no) 
Diuretics (yes, no) 
Date of examination, year 
 
Following the model of causal pathway between magnesium and cardiovascular events, 
analyses were done to check if the criteria for confounding were met or not. The criteria 
needed to be fulfilled to be a confounder is that the possible confounders has to be 
significantly associated with the outcome independent of exposure; possible confounders has 
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to be associated with the exposure and it shouldn’t be in the causal pathway between exposure 
and outcome. 
 
Firstly, in order to check the association between exposure and confounder, spearman 
correlation for the continuous variable and independent sample student T-test for categorical 
variables were used. The P-values ≤0.1 were taken as the rule to select the variable into further 
analysis. 
 
Secondly, in order to check the association between each confounders and different outcomes, 
univariate survival analysis was conducted separately for each of them, predicting if the 
variable was a risk factor for the disease or not. P-values ≤ 0.1 were taken as the rule to select 
the variable into further analysis. 
 
For each outcome events separately, we took those variables as the potential confounding 
variables which showed significant association with both exposure and that particular 
outcome. Variables that were found to be the potential confounders were not the same for all 
outcome events. 
 
Further we calculated hazard ratio (95% CI) of all CVD events (CVD, CVD death, CHD, 
CHD death, AMI, stroke, ischemic stroke, hemorrhagic stroke, SCD or SCA by fourths of 
serum magnesium, adjusting for all the potential confounders using multivariate Cox 
proportional analysis. The two sided P-values of ≤0.05 were considered as statistically 
significant for the analysis. 
 
All the statistical analyses were performed using statistical software SPSS version 19. 
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5 RESULTS 
 
5.1 Dietary magnesium intake 
 
Table 1: One way ANOVA showing mean, SD and post hoc analysis of dependent variable 
(serum magnesium) for each category of dietary magnesium. 
Dietary magnesium Mean±SD Post hoc 
Q1 (<372.23 mg/d) 19.84±1.63 1 (ref) 
Q2(372.27-412.59 mg/d) 19.99±1.54 -0.16 (0.69) 
Q3 (412.63-457.37 mg/d) 19.76±1.52 0.08 (0.36) 
Q4 (>457.42 mg/d) 19.79±1.54 0.04 (0.63) 
Mean ±SD, Mean difference (P-value) 
Q1, Q2, Q3, Q4: fourths of dietary magnesium 
 
There was seen statistical significant difference between groups as determined by one way 
ANOVA (P-value: 0.034). Further post hoc analysis showed that there was statistically 
significant difference in the mean of serum magnesium concentration only when the third 
(19.76) and fourth (19.79) level of dietary magnesium was compared to the second quartile 
(19.99). But there was not seen any statistical significant differences in the mean serum 
magnesium concentration between all other groups of dietary magnesium when compared to 
the first group respectively. Since there was not much change in the mean serum magnesium 
concentration in the various levels of dietary magnesium we decided to do the analysis only as 
per the serum magnesium categories. Also inconsistency between serum and dietary 
estimations, and serum measurement being considered as more reliable indicator of body 
magnesium status became the reason to drop dietary magnesium from further analysis.  
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5.2 Serum magnesium concentration 
 
There was seen statistically significant difference in the mean serum magnesium concentration 
based on absence or presence of CVD mortality (P-value: 0.013) and CHD mortality (P-value: 
0.041). The mean level of serum magnesium concentration was higher in men without the 
event CVD and CHD mortality. But there was not any statistically significant difference in the 
mean serum magnesium concentration based on the presence or absence of CVD, AMI, stroke, 
ischemic stroke, and hemorrhagic stroke, SCD or SCA. But lower serum magnesium is 
associated with the occurrence of fatal events. 
 
Mean dietary magnesium intake was not the same for men based on the absence or presence 
SCD or SCA and non fatal CVD. 
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5.3 Analysis of background characteristics 
 
Table 2: Baseline characteristics among male in KIHD study by quartiles of serum magnesium 
Characteristic Q1 Q2 Q3 Q4 
Rangeof magnesium,mg/l <18.85 18.86–19.85 19.86–20.87 >20.88 
N 636 635 634 635 
Age, year 53.07±5.45 52.46±5.66 53.12±4.90 53.57±4.12 
Years of education 8.41±3.33 8.89±3.50 8.42±3.13 8.79±3.68 
BMI, kg/m2 27.10±3.69 26.71±3.52 26.95±3.49 26.84±3.49 
Energy, KJ 9935.01±2747.64 9864.78±2661.94 9911.03±2592.71 9722.11±2460.27 
Energy expenditure, kcal/d 135.68±163.79 152.20±202.73 136.82±168.18 135.12±156.09 
Alcohol/week, g/d 81.78±162.59 80.44±157.49 71.26±102.04 65.50±108.94 
Mean SBP, mmHg 134.37±17.04 133.79±16.46 134.57±16.73 133.70±17.35 
Mean DBP, mmHg 88.88±10.88 88.42±10.22 89.15±10.26 88.52±10.71 
LDL-chol, mmol/l 3.92±1.02 3.99±1.03 4.06±0.95 4.19±1.01 
HDL-chol, mmol/l 1.30±0.33 1.29±0.29 1.28±0.28 1.29±0.29 
Calcium, mg/d 1168.83±518.95 1162.62±495.70 1204.05±499.70 1168.41±487.85 
Total serum n-3, % 5.47±1.65 5.44±1.63 5.33±1.54 5.32±1.49 
Fiber, g/d 25.53±9.21 25.45±8.94 25.13±8.65 24.32±8.21 
DU-K, mmol/d 85.85±30.01 85.36±26.67 87.30±27.56 85.61±25.05 
Smokers (yes, no) 204 (32.1) 191 (30.1) 208 (32.8) 198 (31.2) 
Diabetes (yes, no) 68 (10.7) 35 (5.5) 24  (3.8) 22  (3.5) 
Elevated BP (yes, no) 388 (61.0) 373 (58.7) 401 (63.2) 369 (58.1) 
CVD in family (yes, no) 513 (80.7) 533 (83.9) 518 (81.7) 521 (82.0) 
CVD history (yes, no) 250 (39.3) 219 (34.5) 223 (35.2) 263 (41.4) 
Magnesium supplementation 
(yes, no) 
- - 2 (3) 2 (3) 
Aspirin medication (yes, no) 42 (6.6) 53 (8.3) 39 (6.2) 23 (3.6) 
Diuretics (yes, no) 48 (7.5) 28 (4.4) 40 (6.3) 53 (8.3) 
Marital status     
Married/living as couple 541 (85.1) 554 (87.2) 554 (87.5) 551 (86.6) 
Single 42 (6.6) 43 (6.8) 40 (6.3) 40 (6.5) 
divorced/widow 53 (8.3) 38 (6.0) 39 (6.2) 44 (6.9) 
Mean±SD, frequency (%) 
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The detailed information regarding the distribution of characteristics in this population across 
the quartiles of serum magnesium is described in Table 1. Men with higher serum magnesium 
concentration intended to have lesser mean alcohol consumption, fiber intake, diabetes 
prevalence, and more LDL cholesterol level. There was not found any constant increase or 
decrease in the value of all other characteristics with increasing serum magnesium 
concentration. There was not much difference in the mean age, BMI, mean systolic and 
diastolic blood pressure across the quartiles of serum magnesium concentration. 
 
Only 2 respondents each in the thirds and fourths of serum magnesium concentration were 
using magnesium supplementation. More than 80% of the respondents in each quartile of 
serum magnesium concentration had a familial history of cardiovascular disease. 
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5.4 Analysis of exposure and possible confounders 
 
Table 3: Spearman correlation between exposure (serum magnesium) and possible 
confounders 
Variables correlation coefficient  Sig (P-value) 
Age, years 0.010 0.622 
Years of education 0.009 0.666 
Body mass index, kg/m2 -0.014 0.471 
Energy, KJ  -0.014 0.486 
Energy expenditure, Kcal/d 0.019 0.347 
Alcohol /week, g/d -0.045 0.025 
Mean systolic BP, mmHg -0.019 0.330 
Mean diastolic BP, mmHg -0.001 0.941 
LDL-chol, mmol/l 0.100 ≤0.001 
HDL-Chol, mmol/l -0.004 0.859 
Calcium, mg/d 0.021 0.298 
Total serum n-3, % -0.037 0.068 
Fiber, g/d -0.041 0.038 
DU-k, (l)mmol/d 0.029 0.209 
Date of examination, year -0.187 ≤0.001 
 
A spearman correlation was done to understand the relationship between the exposure (serum 
magnesium) and the possible confounding variables those were continuous. P-values less than 
or equals to 0.1 were taken as rule to considered the variable to be statistically significant for 
further analysis. Only few variables were found to be statistically significantly correlated with 
serum magnesium concentration and they were total serum n-3, LDL cholesterol, fiber, 
alcohol and date of examination. Among them LDL cholesterol was strongly positively 
correlated with Serum magnesium concentration(r=0.100, P-value ≤0.001) and date of 
examination year was strongly negatively correlated with serum magnesium concentration. 
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For every increase in year there was a decrease in unit serum magnesium concentration by 
18.7%. The other three variables alcohol, fiber and total serum n-3 showed significant 
negative correlation that is they were inversely proportionate to serum magnesium. 
 
 
Table 4: Independent sample T- test between exposure (serum magnesium) and possible 
confounders calculating the mean difference 
Variables (n) Mean diffference (P-value) 
magnesium supplementation 
No (2536) 
Yes (4) 
 
19.84                      (0.005) 
22.05 
Smokers 
No (1739) 
Yes (801) 
 
19.87                      (0.253) 
19.79 
Diabetes  
No (2391) 
Yes (149) 
 
19.89                       (≤0.001) 
19.07 
Elevated blood pressure 
No (1009) 
Yes (1531) 
 
19.90                       (0.15) 
19.81 
CVD in family 
No (455) 
Yes (2085) 
 
19.79                       (0.38) 
19.86 
Diuretics 
No (2371) 
Yes (169) 
 
19.84                       (0.73) 
19.89 
Aspirin medication 
No (2383) 
Yes (157) 
 
19.86                      (0.006) 
19.51 
Marital status 
1 (2200) 
2 (165) 
3 (174) 
 
19.86                      (0.344) (between groups) 
19.81 
19.68 
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The distribution of serum magnesium mg/l was not the same across categories of magnesium 
supplementation, diabetes, and aspirin medication (P = ≤ 0.05) whereas it was same across 
smokers, people with elevated blood pressure, having CVD history in family, diuretics and 
different marital status. Thus magnesium supplementation, diabetes and aspirin medication 
were significantly associated with or were responsible for change in serum magnesium level.  
 
5.5 Analysis of association between possible confounders and outcome events 
 
The results of univariate cox proportional hazard analysis showing hazard ratio for all the 
outcome variables according to each possible confounders are shown in  Table 5. 
 
Variables like body mass index, mean systolic and diastolic blood pressure, elevated blood 
pressure were found to be strongly associated with all the outcome variables showing slight 
increase in risk of getting the outcome when there was a unit increase in those variables.  
 
Diabetes was also found to be strongly significantly associated with all outcome variables 
except for hemorrhagic stroke. The risk of occurrence of all outcome variables except 
hemorrhagic stroke was more than 200% among people with diabetes.  
 
Magnesium supplementation, total serum n-3, energy consumed, energy expenditure, 
potassium did not show significant association with any of the outcome variables. 
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5.6 Association of serum magnesium with all CVD outcomes 
 
5.6.1 Association with CVD and CVD death 
 
From the previous analysis LDL, fiber, aspirin medication, date of examination, alcohol 
intake, diabetes were found to be the potential confounders for CVD incidence and CVD 
mortality. Based on this result multivariate Cox hazard analysis was done for both CVD and 
CVD death adjusting for potential confounders. 
 
Table 6: Hazard ratio of CVD incidence (n =1582) by total serum magnesium concentration, 
both adjusted and unadjusted for confounders 
Variables (unit) HR (95% CI) P-value  
Serum magnesium (mg/l) 0.98 (0.95, 1.02) 0.36 
Diabetes (yes, no) 2.07 (1.71, 2.51) <0.001 
LDL-chol (mmol/l) 1.15 (1.10, 1.21) < 0.001 
Fiber (g/d) 0.99 (0.98, 0.10) 0.002 
Aspirin medication (yes, no) 1.41 (1.16, 1.72) 0.001 
Date of examination (year) 0.97 (0.94, 1.00) 0.11 
Alcohol /week (g/d) 1.00 (1.00, 1.00) 0.16 
Unadjusted serum 
magnesium (mg/l) 
0.99 (0.95, 1.02) 0.41 
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Table 7: Hazard ratio of CVD death (n = 491) by total serum magnesium concentration, both 
adjusted and unadjusted for confounders 
Variables (unit) HR (95% CI) P- value  
Serum magnesium (mg/l) 0.91 (0.85, 0.96) 0.001 
Diabetes (yes, no) 2.98 (2.27, 3.89) <0.001 
LDL-chol (mmol/l) 1.16 (1.07, 1.27) 0.001 
Fiber (g/d)  0.98 (0.97, 0.99) 0.005 
Aspirin medication (yes, no) 1.48 (1.06, 2.07) 0.02 
Date of examination (year) 0.94 (0.88, 0.10) 0.04 
Alcohol /week (g/d) 1.00 (1.00, 1.00) <0.001 
Unadjusted serum 
magnesium (mg/l) 
0.89 (0.84, 0.94) <0.001 
Q1, Q2, Q3, Q4: fourths of serum magnesium concentration 
 
We found that with an increase in a unit serum magnesium concentration, risk of CVD death 
decreased by 9% (HR: 0.91, 95% CI: 0.85, 0.96) after adjusting for all other confounders. The 
result was almost the same also for unadjusted serum magnesium concentration. 
 
Both adjusted and unadjusted serum magnesium concentration were not found to have 
association with CVD incidence. However diabetes was strongly associated with both CVD 
incidence and death. 
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Table 8: Hazard ratio of CVD incidence (n = 1582) by quartiles of serum magnesium 
concentration, adjusted for confounders 
Variables (unit) HR (95% CI) P- value  
Q1(<18.85 mg/l) 1 (ref)  
Q2 (18.86-19.85 mg/l) 0.89 (0.77, 1.03) 0.11 
Q3 (19.86-20.87 mg/l) 0.99 (0.86, 1.14) 0.89 
Q4 (>20.88 mg/l) 0.96 (0.83, 1.10) 0.54 
Diabetes (yes, no) 2.08 (1.71, 2.52) <0.001 
LDL-chol (mmol/l) 1.15 (1.10, 1.21) <0.001 
Fiber (g/d)  0.99 (0.98, 0.10) 0.002 
Aspirin medication (yes, no) 1.41 (1.16, 1.72) 0.001 
Date of examination (year) 0.98 (0.95, 1.00) 0.16 
Alcohol /week (g/d) 1.00 (1.00, 1.00) 0.15 
Q1, Q2, Q3, Q4: fourths of serum magnesium concentration 
 
Table 9: Hazard ratio of CVD death (n = 491) by quartiles of serum magnesium concentration, 
adjusted for confounders 
Variables (unit) HR (95% CI) P- value  
Q1(<18.85mg/l) 1 (ref)  
Q2 (18.86-19.85mg/l) 0.74 (0.57, 0.94) 0.02 
Q3 (19.86-20.87mg/l) 0.75 (0.59, 0.97) 0.03 
Q4 (>20.88mg/l) 0.74 (0.57, 0.95) 0.02 
Diabetes (yes, no) 3.02 (2.31, 3.95) <0.001 
LDL-chol (mmol/l) 1.16 (1.06, 1.26) 0.001 
Fiber (g/d)  0.98 (0.97, 0.99) 0.005 
Aspirin medication (yes, no) 1.51 (1.08, 2.11) 0.01 
Date of examination (year) 0.95 (0.89, 1.00) 0.06 
Alcohol /week (g/d) 1.00 (1.00, 1.00) <0.001 
Q1, Q2, Q3, Q4: fourths of serum magnesium concentration 
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All quartiles of serum magnesium concentration were significantly inversely associated with 
CVD death. Men in the highest quartile of serum magnesium concentration had the lowest risk 
(HR: 0.74, 95% CI: 0.57, 0.95) of CVD death compared to the men in the lowest quartile.  
LDL, fiber, aspirin medication, date of examination, diabetes were all found to be associated 
with CVD mortality.  
 
After adjusting for confounders, quartiles of serum magnesium were not associated with the 
risk of CVD incidence. 
 
 
5.6.2 Association with CHD incidence and mortality 
 
From the above analysis LDL, aspirin medications, date of examination year, diabetes were 
found to be the confounders of both CHD incidence and CHD death. Whereas fiber was found 
to be the confounding variable for only CHD incidence and alcohol intake was found to be the 
confounding variable for CHD death 
 
Table 10: Hazard ratio of CHD incidence (n = 930) by serum magnesium concentration, both 
adjusted and unadjusted for confounders 
Variables (unit) HR (95% CI) P- value 
Serum magnesium (mg/l) 1.00 (0.96, 1.04) 0.95 
Diabetes (yes, no) 2.65 (2.12, 3.33) <0.001 
LDL-Chol (mmol/l) 1.28 (1.21, 1.37) <0.001 
Aspirin medication (yes, no) 1.74 (1.37, 2.21) <0.001 
Fiber (g/d) 0.99 (0.98, 1.00) 0.06 
Date of examination (year) 0.96 (0.92, 1.00) 0.06 
Unadjusted serum 
magnesium (mg/l) 
1 (0.96, 1.04) 0.94 
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Table 11: Hazard ratio of CHD death (n = 332) by serum magnesium concentration, both 
adjusted and unadjusted for confounders 
Variables (unit) HR (95% CI) P- value 
Serum magnesium (mg/l) 0.91 (0.85, 0.98) 0.01 
Diabetes (yes, no) 3.43 (2.51, 4.69) <0.001 
LDL-Chol (mmol/l) 1.25 (1.13, 1.39) <0.001 
Aspirin medication (yes, no) 1.57 (1.05, 2.33) 0.03 
Alcohol intake (g/d) 1.00 (1.00, 1.00) 0.003 
Date of examination (year) 0.95 (0.88, 1.02) 0.13 
Unadjusted serum 
magnesium (mg/l) 
0.89 (0.83, 0.95) 0.001 
 
Total serum magnesium concentration was strongly associated with CHD mortality but was 
not found to be associated with CHD incidence after adjusting for potential confounders. The 
findings were similar also for unadjusted serum magnesium concentration. Increase in serum 
magnesium concentration by 1 unit, decreased the risk of CHD death by 9% after adjusting for 
all the potential confounders. All other confounders except date of examination were found to 
be strongly associated with CHD incidence and death. 
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Table 12: Hazard ratio for CHD incidence (n = 930) by quartiles of serum magnesium, 
adjusted for confounders 
Variables (unit) HR (95%CI) P- value  
Q1 (<18.85mg/l) 1 (ref)  
Q2 (18.86-19.85mg/l) 0.86 (0.72, 1.04) 0.13 
Q3 (19.86-20.87mg/l) 1.06 (0.88, 1.27) 0.55 
Q4 (>20.88mg/l) 0.95 (0.79, 1.14) 0.59 
Diabetes (yes, no) 2.65 (2.11, 3.32) <0.001 
LDL-Chol (mmol/l) 1.29 (1.21, 1.37) <0.001 
Aspirin medication (yes, no) 1.74 (1.37, 2.21) <0.001 
Date of examination (year) 0.96 (0.92, 1.00) 0.08 
Fiber (g/d)  0.99 (0.98, 1.00) 0.06 
Q1, Q2, Q3, Q4: fourths of serum magnesium concentration 
 
Table 13: Hazard ratio for CHD death (n = 332) by quartiles of serum magnesium, adjusted 
for confounders 
Variables (unit) HR (95%CI) P- value  
Q1 (<18.85mg/l) 1  
Q2 (18.86-19.85mg/l) 0.71(0.53, 0.96) 0.03 
Q3 (19.86-20.87mg/l) 0.70 (0.52, 0.95) 0.02 
Q4 (>20.88mg/l) 0.72 (0.53, 0.97) 0.03 
Diabetes (yes, no) 3.44 (2.52, 4.70) <0.001 
LDL-Chol (mmol/l) 1.25 ( 1.13, 1.39) <0.001 
Aspirin medication (yes, no) 1.6 (1.07, 2.37) 0.02 
Alcohol intake/week (g/d) 1.00 (1.00, 1.00) 0.001 
Date of examination (year) 0.95 (0.88, 1.02) 0.17 
Q1, Q2, Q3, Q4: fourths of serum magnesium concentration 
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All the fourths of serum magnesium concentration were strongly associated with CHD death 
after adjusting for all the confounders. However the risk of death due to CHD did not vary 
much among the quartiles of serum magnesium concentration. Fourths of serum magnesium 
concentration were not found to be associated with CHD incidence.  
 
5.6.3 Association with AMI 
 
From the previous analysis LDL cholesterol, fiber, aspirin medication, date of examination 
year, and diabetes were derived as the confounders for AMI. 
 
Table 14: Hazard ratio of AMI (n = 732) by total serum magnesium concentration, both 
adjusted and unadjusted for confounders 
Variables (unit) HR (95% CI) P- value  
Serum magnesium (mg/l) 1.00 (0.95, 1.04) 0.88 
Diabetes (yes, no) 3.1 (2.45, 3.92) <0.001 
LDL-chol (mmol/l) 1.33 (1.24, 1.43) <0.001 
Fibre (g/d) 0.99 (0.98, 1.00) 0.03 
Aspirin medication (yes, no) 1.48 (1.12, 1.95) 0.005 
Date of examination (year) 0.96 (0.92, 1.01) 0.09 
Unadjusted serum 
magnesium (mg/l) 
0.99 (0.95, 1.04) 0.83 
 
Total serum magnesium concentration when unadjusted was not found to be associated with 
risk of AMI. The result was same also when adjusted for its confounders. Instead all other 
confounders except date of examination were found to be strongly associated with AMI. 
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Table 15: Hazard ratio of AMI (n = 732) by quartiles of serum magnesium concentration, 
adjusted for confounders 
Variables (unit) HR (95%CI) P- value 
Q1 (<18.85mg/l) 1 (ref)  
Q2 (18.86-19.85mg/l) 0.79 (0.64, 0.98) 0.03 
Q3 (19.86-20.87mg/l) 1.01 (0.83, 1.24) 0.90 
Q4 (>20.88mg/l) 0.96 (0.78, 1.18) 0.69 
Diabetes (yes, no) 3.07 (2..42, 3.88) <0.001 
LDL-chol (mmol/l) 1.33 (1.24, 1.43) <0.001 
Fiber (g/d)  0.99 (0.98, 1.0) 0.03 
Aspirin medication (yes, no) 1.49 (1.13, 1.96) 0.005 
Date of examination (year) 0.96 (0.92, 1.01) 0.13 
Q1, Q2, Q3, Q4: fourths of serum magnesium concentration 
 
Serum magnesium only in the seconds, comparing to the lowest quartile was associated with 
risk of AMI. There was 21% decrease in the risk of AMI among men belonging to second 
quartile than in the lowest quartile of serum magnesium concentration after adjusting for fiber, 
aspirin medication and date of examination year, diabetes. Adjusted LDL (HR: 1.33; 95% CI: 
1.24, 1.43), diabetes (HR: 3.07, 95% CI: 2.42, 3.88) and aspirin medication (HR: 1.49, 95% 
CI: 1.13, 1.96) were found to increase the risk of occurrence of AMI. 
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5.6.4 Association with SCD or SCA 
 
LDL, fiber, aspirin medication, alcohol intake, diabetes were found to be the potential 
confounders for sudden cardiac death or sudden cardiac arrest from the various analyses done 
above. 
 
Table 16: Hazard ratio SCD24 or cardiac arrest (n = 232) by total serum magnesium 
concentration, both adjusted and unadjusted for confounders 
Variables HR (95% CI) P- value 
Serum magnesium (mg/l) 0.91 (0.84, 0.99) 0.13 
Diabetes (yes, no) 3.00 (2.03, 4.44) <0.00 
LDL-chol (mmol/l) 1.24 (1.09, 1.39) <0.001 
Fiber (g/d)  0.99 (0.97, 1.01) 0.31 
Aspirin medication (yes, no) 1.46 (0.91, 2.34) 0.08 
Alcohol /week (g/d) 1.00 (1.00, 1.00) 0.01 
Unadjusted serum 
magnesium (mg/l) 
0.92 (0.84, 0.99) 0.03 
 
Increase in serum magnesium concentration by 1 unit decreased the risk of SCD by 8% when 
it was not adjusted for it confounder. After further adjustment, total serum magnesium 
concentration was not found to be associated with SCD24. Also LDL and diabetes were 
significant risk factors for SCD whereas alcohol intake neither increased nor decreased the 
risk of SCD. 
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Table 17: Hazard ratio SCD24 or cardiac arrest (n = 232) by quartiles of serum magnesium 
concentration, adjusted for confounders 
Variables (unit) HR (95% CI)  P- value 
Q1 (<18.85mg/l) 1 (ref)  
Q2 (18.86-19.85mg/l) 0.69 (0.47, 0.99) 0.05 
Q3 (19.86-20.87mg/l) 0.82 (0.58, 1.17) 0.28 
Q4 (>20.88mg/l) 0.76 (0.53, 1.09) 0.13 
Diabetes (yes, no) 2.99 (2.02, 4.42) <0.001 
LDL-chol (mmol/l) 1.24 (1.10, 1.10) <0.001 
Fiber (g/d) 0.99 (0.97, 1.01) 0.31 
Aspirin medication (yes, no) 1.54 (0.96, 2.46) 0.07 
Alcohol /week (g/d) 1.00 (1.00, 1.00) 0.004 
Q1, Q2, Q3, Q4: fourths of serum magnesium concentration 
 
Adjusted multivariate cox proportional hazard showed that men in the second quartile (0.69, 
95% CI: 0.47, 0.99) of serum magnesium concentration had significant lower risk of SCD 
compared to the lowest quartile of serum magnesium concentration. 
 
5.6.5 Associations with stroke, ischemic stroke and hemorrhagic stroke 
  
From the above analysis we found that only diabetes was significantly associated with both 
serum magnesium and outcome variable stroke and ischemic stroke, i.e only diabetes was 
found as the confounder for both ischemic and hemorrhagic stroke. Fiber was found to be the 
potential confounder for hemorrhagic stroke. 
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Table 18: Hazard ratio of stroke (n = 226) by total serum magnesium concentration, both 
adjusted and unadjusted for confounder 
Stroke HR (95% CI) P- value  
Serum magnesium (mg/l) 0.96 (0.88, 1.04) 0.341 
Diabetes (yes, no) 2.69 (1.8, 4.02) <0.001 
Unadjusted serum magnesium 
(mg/l) 
0.93 (0.86, 1.02) 0.11 
 
Table 19: Hazard ratio of ischemic stroke (n = 182) by total serum magnesium concentration, 
both adjusted and unadjusted for confounder 
Ischemic stroke HR (95% CI) P- value 
Serum magnesium (mg/l) 0.97 (0.89, 1.07) 0.56 
Diabetes (yes, no) 3.04 (1.97, 4.67) <0.001 
Unadjusted serum 
magnesium (mg/l) 
0.94 (0.86, 1.02) 0.22 
 
Table 20: Hazard ratio of hemorrhagic stroke (n = 47) by total serum magnesium concentration, 
adjusted for confounder 
Hemorrhagic stroke HR (95% CI) P- value 
Serum magnesium (mg/l) 0.90 (0.75, 1.08) 0.28 
Fiber (g/d)  0.95 (0.92, 0.99) 0.01 
Unadjusted serum 
magnesium (mg/l) 
0.91 (0.76, 1.09) 0.31 
 
There was not found any significant association between total serum magnesium concentration 
(both adjusted and unadjusted) and the occurrence of stroke, ischemic stroke, and hemorrhagic 
stroke (Table.18, 19, 20). However the respective confounding variable fiber was found to be 
associated for slight decrease in the risk of hemorrhagic stroke and diabetes was found to be 
associated with increase in risk of stroke and ischemic stroke after adjustment of serum 
magnesium 
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Table 21: Hazard ratio of stroke (n = 226) by quartiles of serum magnesium, adjusted for 
confounder 
 
 
Table 22: Hazard ratio of ischemic stroke (n = 182) by quartiles of serum magnesium, adjusted 
for confounder 
Variables (unit) HR (95% CI) P- value 
Q1(<18.85mg/l) 1 (ref)  
Q2 (18.86-19.85mg/l) 1.0 (0.66, 1.50) 0.99 
Q3 (19.86-20.87mg/l) 1.08 (0.72, 1.62) 0.72 
Q4 (>20.88mg/l) 0.88 (0.58, 1.35) 0.57 
Diabetes (yes, no) 3.09 (2.01, 4.75) <0.001 
 
 
 
 
 
 
 
 
 
 
 
Variables (unit) HR (95% CI) P- value 
Q1(<18.85mg/l) 1 (ref)  
Q2 (18.86-19.85mg/l) 0.89 (0.62, 1.29) 0.55 
Q3 (19.86-20.87mg/l) 1.08 (0.75, 1.55) 0.67 
Q4 (>20.88mg/l) 0.86 (0.59, 1.25) 0.43 
Diabetes (yes, no) 2.75 (1.84, 4.11) <0.001 
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Table 23: Hazard ratio of hemorrhagic stroke (n = 47) by quartiles of serum magnesium, 
adjusted for confounder 
Variables (unit) HR (95% CI) P- value 
Q1(<18.85mg/l) 1 (ref)  
Q2 (18.86-19.85mg/l) 0.78 (0.34, 1.81) 0.56 
Q3 (19.86-20.87mg/l) 1.18 (0.55, 2.52) 0.67 
Q4 (>20.88mg/l) 0.75 (0.32, 1.74) 0.50 
Fiber (g/d) 0.95 (0.91, 0.99) 0.01 
 
 
There was not any association between quartiles of serum magnesium concentration and 
stroke, ischemic stroke and hemorrhagic stroke after adjusting for confounders.   
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6 DISCUSSION 
 
In this prospective cohort of Finnish men, change in total serum magnesium concentration by 
a unit, was associated with lower risk of CVD, CHD and SCD mortality when unadjusted. But 
after adjusting for the potential confounders, total serum magnesium concentration was found 
to be associated only with CVD and CHD mortality. When compared to the quartiles of serum 
magnesium concentration, highest serum magnesium concentration was very strongly 
associated with the lower risk of CVD and CHD mortality. Men with highest serum 
magnesium concentration had 26% lower risk of CVD death and 28% lower risk of CHD 
death after adjusting for its potential confounders. Total serum magnesium concentration was 
not associated with non-fatal CVD, CHD and AMI after controlling for their risk factors. But 
there was found significant decrease in risk of non-fatal AMI and fatal SCD in the second 
quartile compared to the lowest quartile of serum magnesium concentration. Serum 
magnesium concentration was not found to be associated with stroke, ischemic stroke, and 
hemorrhagic stroke at any condition. 
 
There are conflicting results in many previous studies regarding the association between 
magnesium and all the outcome events. There are many studies based on dietary magnesium 
intake which has either gone against or in a support of our study findings (Guasch-Ferre et al. 
2014; Stevanovic et al. 2011; Al-Delaimy et al. 2004). These studies based on dietary 
measures might be influenced by residual confounding or recall bias. And also diet or food 
rich in magnesium may contain other nutrient factors which might have influenced the CVD 
outcomes and its risk factors. There are only few studies which have examined the association 
between serum magnesium and CVD events. Similar to our result serum magnesium was not 
found to be associated with CVD (Khan et al. 2010). A prospective study showed no 
significant association with serum magnesium concentration and stroke after adjusting for 
potential confounders (Ohira et al. 2009). Consistent with other studies result there was not 
found any association between serum magnesium concentration and stroke after adjusting for 
potential confounders. In our study there was seen significant lower risk of SCD when 
unadjusted but when it was adjusted for confounders there was not seen any association 
between total serum magnesium concentration and SCD. When divided into fourths there was 
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seen a significant lowest risk of SCD in the second lowest quartile of serum magnesium 
concentration. Though the result supported the finding of other studies that serum magnesium 
is associated with lower risk of SCD it did not support other studies finding stating that there 
is the lowest risk of SCD in the highest serum magnesium concentration (Chiuve et al. 2011; 
peacock et al. 2010). Similar to other studies serum magnesium concentration was strongly 
associated with fatal CHD but not with CHD incidence (Ford 1999; Chiuve et al. 2013). In 
contrast few studies have shown no effect of magnesium on CHD. Similar to serum 
magnesium concentration many studies showed the association between dietary intake of 
magnesium and risk of cardiovascular events (Lian et al. 2011; Al-Delaimy et al. 2004). 
 
Magnesium is an intracellular cation, so serum magnesium may not represent the total body 
magnesium stores (Jahnen-Dechent and Ketteler 2012). However measurement of serum 
magnesium is the easiest, cheapest and most common laboratory measurement and also serum 
magnesium concentration can be correlated with the intracellular magnesium. 
 
Magnesium affects the movement of sodium, potassium and calcium (Swaminathan 2003), 
which may lead to affect in the cardiovascular system resulting in increased risk. However in 
our study there was not seen any significant correlation between serum magnesium 
concentration and calcium and potassium. Magnesium and many CVD outcomes were found 
to be associated with hypertension, diabetes, and alcohol (Ma et al. 1995; Romani 2008). Thus 
one of the important finding of this study was the exploration of factors that might affect the 
association between magnesium and cardiovascular events. We found that alcohol intake, 
fiber, aspirin medication, date of examination, diabetes were statistically affecting both the 
serum magnesium concentration and CVD mortality. Diabetes was one of the variables which 
was found to be strongly associated with the change in magnesium level as renal magnesium 
wasting and osmotic diuresis causes magnesium depletion. In contrast magnesium depletion 
also affects insulin secretion and insulin resistance (Takaya et al. 2004). Also diabetes 
independently was a very strong factor predicting almost 200% increased risk of CVD 
outcomes except hemorrhagic stroke. However even after adjusting for these potential 
confounders, serum magnesium remained strongly associated with CVD mortality. There was 
no association between total serum magnesium concentration and CVD after adjustment for all 
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the biomarkers. These results suggest that magnesium can protect fatal CVD. Clinical trials 
also had shown both protective and no effect of magnesium infusion in patient to prevent from 
arrhythmias (Roffe et al.1994; Gyamlani et al. 2000). Thus further clinical trials are needed to 
know antithrombotic effect of magnesium to prevent AMI. 
 
 
7 STRENGTHS AND LIMITATIONS OF THE STUDY 
 
The strength of this study is that it is a prospective population based study that includes 
reliable sample size at baseline and follow up. We had reliable definitions of all the outcome 
variables as they were based on ICD-10 diagnoses. The outcomes were based on the diagnosis 
available from the National Hospital Discharge Registry, the National Causes of Death 
Registry and FINMONICA registry which are very reliable sources of information. The level 
of magnesium was based on the measurement of serum magnesium concentration present in 
the body. The method used to measure serum magnesium concentration was atomic absorption 
spectrometry. Hence it has high level of accuracy. 
 
The study also has few limitations like the study only includes male population so it cannot be 
generalized to women. Serum magnesium represents very small part of total body magnesium 
so it may not reflect if there is really a deficiency of magnesium in our body which is 
increasing or decreasing the risk of CVD events. 
 
8 CONCLUSION 
 
In conclusion there was strong relation between serum magnesium concentration and CVD, 
CHD mortality. Increase in serum magnesium concentration decreased the occurrence of fatal 
CVD and CHD. Total serum magnesium concentration was found to be associated with SCD 
only when it was unadjusted. However total serum magnesium concentrations was not found 
to be associated with incidence of CVD, CHD, AMI and stroke risk both before and after 
adjusting for its potential confounders. But serum magnesium concentration when divided into 
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fourths showed significant decrease in risk in the second quartile of AMI incidence and SCD 
and in all fourths of fatal CVD and CHD when compared to the lowest quartile. 
 
 However, further studies including clinical and randomized controlled trials are needed to 
clearly state the importance of magnesium and to recommend magnesium rich food stating its 
protective effect for cardiovascular outcomes. 
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